课题基金 / 基金详情

Endothelial TAK1 Signaling and Resolution of Pulmonary Edema in Sepsis

Endothelial TAK1 Signaling and Resolution of Pulmonary Edema in Sepsis
脓毒症肺水肿的内皮 TAK1 信号转导和解决
批准号:
9535680
负责人:
CHINNASWAMY TIRUPPATHI
金额:
$4.55万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-01 至 2020-01-31

项目摘要

项目成果

CHINNASWAMY TIRUPPATHI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Sepsis associated with acute lung injury (ALI) is a common cause of death in hospitalized patients. ALI is in large part the result of lung vascular leakage and protein rich edema and there is a lack of effective therapy. Here, we have proposed a novel strategy to reverse ALI by stimulating an endogenous recovery process that is usually activated after lung injury. Thrombin, an edema-genic factor generated during sepsis, mediates pulmonary vascular leakage by activating protease-activated receptor-1 (PAR-1) on the endothelial cell surface. PAR-1-induced Ca2+ entry via store-operated Ca2+-entry channels (SOCs), disassembles endothelial adherens junctions (AJs) to cause increased lung vascular leak. An endoplasmic reticulum (ER) localized Ca2+ sensor protein stromal interacting molecule-1 (STIM1), is crucial for activating SOC to induce store- operated Ca2+-entry (SOCE) in endothelial cells (ECs). Now, we have identified in a murine model of tamoxifen-inducible endothelial cell (EC)-restricted TAK1 (Map3k7) deletion (Map3k7i∆EC), a key role for TAK1 in resolving PAR-1-mediated pulmonary edema formation through regulation of the functions of STIM1, glycogen synthase kinase-3β (GSK-3β) and β-catenin in ECs. We made the following observations (Supporting Data): i) TAK1 null ECs exhibited augmented SOCE and permeability in response to PAR-1 activation; ii) PAR-1-induced lung vascular permeability in vivo was not reversible in Map3k7i∆EC mice; iii) β- catenin expression was markedly reduced in ECs of Map3k7i∆EC mice; iv) glycogen synthase kinase-3β (GSK- 3β) was persistently active in ECs of Map3k7i∆EC mice, which may account for the markedly reduced expression of β-catenin in ECs of Map3k7i∆EC mice; v) PAR-1-medatied TAK1 activation was prevented in ECs of EC-restricted STIM1 knockout (Stim1∆EC) mice; vi) surprisingly, we observed that SOCE signals the inactivation of GSK-3β via TAK1 activation in ECs; vii) importantly, PAR-1-mediated lung vascular leak was markedly reduced in tamoxifen-inducible EC-restricted GSK-3β knockout (GSK-3βi∆EC) mice. Based on these novel observations, in Aim 1, we will test the hypothesis that TAK1 activation secondary to STIM1-mediated SOCE induces STIM1 phosphorylation which in turn inhibits SOCE and dampens lung vascular permeability. In Aim 2, we will test the hypothesis that TAK1 activation secondary to STIM1-mediated SOCE phosphorylates GSK-3β to inactivate GSK-3β, which in turn promotes increased β-catenin expression at endothelial AJs to restore endothelial barrier integrity and thereby resolves pulmonary edema. A better understanding of the signaling mechanisms of TAK1 functions downstream of SOCE will lead to novel therapeutic approaches that will resolve pulmonary edema in sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
  • 批准号:
    10488226
  • 项目类别:
  • 资助金额:
    $3.2万
  • 财政年份:
    2021
  • 负责人:
    CHINNASWAMY TIRUPPATHI
  • 依托单位:
Transcription Factor Elf2 Signals Resolution of Lung Injury
  • 批准号:
    10363718
  • 项目类别:
  • 资助金额:
    $51.97万
  • 财政年份:
    2021
  • 负责人:
    CHINNASWAMY TIRUPPATHI
  • 依托单位:
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
  • 批准号:
    10297258
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2021
  • 负责人:
    CHINNASWAMY TIRUPPATHI
  • 依托单位:
Transcription Factor Elf2 Signals Resolution of Lung Injury
  • 批准号:
    10178835
  • 项目类别:
  • 资助金额:
    $51.97万
  • 财政年份:
    2021
  • 负责人:
    CHINNASWAMY TIRUPPATHI
  • 依托单位:
海外基金